Monoferric is a drug owned by Pharmacosmos As. It is protected by 5 US drug patents filed from 2020 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 22, 2036. Details of Monoferric's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8815301 | Stable iron oligosaccharide compound |
Aug, 2029
(4 years from now) | Active |
| US12030962 | Stable iron oligosaccharide compound |
Mar, 2029
(4 years from now) | Active |
| US11851504 | Stable iron oligosaccharide compound |
Mar, 2029
(4 years from now) | Active |
| US10414831 | Stable iron oligosaccharide compound |
Mar, 2029
(4 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11633489 | Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant |
Jun, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Monoferric's patents.
Latest Legal Activities on Monoferric's Patents
Given below is the list of recent legal activities going on the following patents of Monoferric.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Electronic Review Critical | 27 Apr, 2023 | US11633489 |
| Email Notification Critical | 27 Apr, 2023 | US11633489 |
| Mail Miscellaneous Communication to Applicant | 27 Apr, 2023 | US11633489 |
| Recordation of Patent eGrant | 25 Apr, 2023 | US11633489 |
| Miscellaneous Communication to Applicant - No Action Count | 25 Apr, 2023 | US11633489 |
| Patent Issue Date Used in PTA Calculation Critical | 25 Apr, 2023 | US11633489 |
| Recordation of Patent Grant Mailed Critical | 25 Apr, 2023 | US11633489 |
| Email Notification Critical | 06 Apr, 2023 | US11633489 |
| Issue Notification Mailed Critical | 05 Apr, 2023 | US11633489 |
| Email Notification Critical | 15 Mar, 2023 | US11633489 |
US patents provide insights into the exclusivity only within the United States, but Monoferric is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Monoferric's family patents as well as insights into ongoing legal events on those patents.
Monoferric's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Monoferric's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 22, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Monoferric Generics:
There are no approved generic versions for Monoferric as of now.
About Monoferric
Monoferric is a drug owned by Pharmacosmos As. It is used for treating iron deficiency anemia in adult patients with intolerance to oral iron or unsatisfactory response to oral iron, and non-hemodialysis dependent chronic kidney disease, by administering ferric derisomaltose. Monoferric uses Ferric Derisomaltose as an active ingredient. Monoferric was launched by Pharmacosmos in 2020.
Approval Date:
Monoferric was approved by FDA for market use on 16 January, 2020.
Active Ingredient:
Monoferric uses Ferric Derisomaltose as the active ingredient. Check out other Drugs and Companies using Ferric Derisomaltose ingredient
Treatment:
Monoferric is used for treating iron deficiency anemia in adult patients with intolerance to oral iron or unsatisfactory response to oral iron, and non-hemodialysis dependent chronic kidney disease, by administering ferric derisomaltose.
Dosage:
Monoferric is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG/5ML (100MG/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| 100MG/ML (100MG/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| 1GM/10ML (100MG/ML) | SOLUTION | Prescription | INTRAVENOUS |